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Abbreviations: 28 
25(OH)D - 25-hydroxyvitamin D 29 
CBA   – cytometric bead array 30 
CRP   - C reactive protein 31 
p38-MAPK  - p38 mitogen-activated protein kinase 32 
Tregs   - T regulatory cells  33 
TRM  - resident-memory T cells  34 
VZV   - Varicella Zoster Virus  35 
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Abstract: 36 
Ageing is associated with increased number of infections, decreased vaccine efficacy and 37 
increased systemic inflammation termed inflammageing. These changes are reflected by 38 
reduced recall responses to varicella zoster virus (VZV) challenge in the skin of older adults. 39 
Vitamin D increases immunoregulatory mechanisms and has the potential to inhibit 40 
inflammageing. Since vitamin D deficiency is more common in the old and has been 41 
associated with frailty and increased inflammation. Therefore we investigated the use of 42 
vitamin D3 replacement to enhance cutaneous antigen-specific immunity in older adults (≥65 43 
years). 44 
We showed that that older adults had reduced VZV-specific cutaneous immune response 45 
and increased non-specific inflammation as compared to young. Increased non-specific 46 
inflammation observed in the skin of older adults negatively correlated with vitamin D 47 
sufficiency. Therefore, vitamin D3 replacement was investigated to determine if it could 48 
improve VZV-specific cutaneous immune responses in older adults. Vitamin D insufficient 49 
older adults (n=18) were administered 6400IU of vitamin D3/day orally for 14 weeks. Antigen-50 
specific immunity to VZV was assessed using transcriptional analysis of skin biopsies 51 
collected from challenged injection sites pre- and post-vitamin D3 replacement. We showed 52 
that vitamin D3 supplementation significantly increased the response to cutaneous VZV 53 
antigen challenge in older adults. This enhancement was associated with a reduction in 54 
inflammatory monocyte infiltration with a concomitant enhancement of T cell recruitment to 55 
the site of antigen challenge in the skin. 56 
In conclusion vitamin D3 replacement can boost antigen-specific immunity in older adults with 57 
sub-optimal vitamin D status.   58 
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Introduction: 59 
Immunity decreases during ageing as demonstrated by the increased susceptibility to 60 
bacterial and viral infections, re-activation of latent infections such as varicella zoster virus 61 
(VZV), decreased vaccine efficacy and increased incidence of cancer (1-3). In addition, there 62 
is an increase in low grade systemic inflammation in older humans termed inflammageing. 63 
This is characterised by high serum levels of the inflammatory cytokines IL-6, IL-1β, TNFα 64 
and C reactive protein (CRP) (4), and is a strong predictor for frailty and mortality (5, 6). 65 
Inflammageing is also believed to contribute to reduced antigen-specific immunity that is 66 
observed with older age (≥65 years) (7, 8). 67 
Antigen-specific cutaneous recall responses are reduced in healthy old as compared to 68 
young individuals (8-11). We have shown that intradermal injections of air, saline or antigen 69 
into the skin of older adults are associated with induction of an early non-specific 70 
inflammation which directly contributes to reduced secondary cutaneous immunity (12). We 71 
proposed that this non-specific inflammation is driven by senescent fibroblasts recruiting 72 
inflammatory monocytes that secrete PGE2 and directly inhibit antigen-specific immunity 73 
(12). Blockade of inflammation using the anti-inflammatory drug Losmapimod (a specific p38 74 
MAP kinase inhibitor) can restore antigen-specific immunity in older adults via inhibiting the 75 
non-specific inflammation in the skin (8, 12).  76 
Vitamin D has key immunomodulatory properties including increasing the abundance of 77 
regulatory T cells (Tregs) (13-15), reducing inflammatory cytokine production by T cells and 78 
monocytes (16, 17) as well as increasing antimicrobial peptide production (18). Vitamin D 79 
insufficiency, as determined by serum 25-hydroxyvitamin D (25[OH]D) levels <75nmol/L, is 80 
more common in the older adult (>65 years) population, particularly in those who are frail 81 
and who have elevated inflammatory markers (19-21). Therefore, vitamin D insufficiency 82 
may exacerbate inflammageing and non-specific inflammation observed in older adults. 83 
As vitamin D insufficiency is associated with ageing and inflammation, we initiated a clinical 84 
study using vitamin D replacement in older adults with sub-optimal vitamin D status to 85 
assess if vitamin D3 replacement improves secondary cutaneous immunity. Older adults with 86 
vitamin D insufficiency (25(OH)D <75 nmol/L), were orally administered 6400IU of vitamin D3 87 
per day for 14 weeks. Antigen-specific immunity was assessed by measuring the clinical 88 
response to VZV challenge and by transcriptional analysis of skin biopsies collected pre- and 89 
post-vitamin D3 replacement. We show that vitamin D3 replacement can significantly improve 90 
VZV-specific cutaneous immunity in older adults. Vitamin D therefore has the potential to be 91 
used as a cheap, safe and effective therapy to enhance antigen-specific immunity in the skin 92 
of elderly humans.  93 
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Materials and Methods: 94 
Study approval: 95 
This study was approved by the NHS Queen Square Research Ethics Committee (reference 96 
17/SC/0196) and by the UCL Research Ethics Committee. All participants provided written 97 
informed consent and study procedures were performed in accordance with the principles of 98 
the declaration of Helsinki. We were advised by the UK’s Medicines and Healthcare products 99 
Regulatory Agency (MHRA) that the study was not classified as a Clinical Trial of an 100 
Investigational Medicinal Product (IMP) as defined by the EU Directive 2001/20/EC. As this 101 
experimental medicine study was designed to test a hypothesis in humans in vivo and not to 102 
determine the therapeutic outcome or efficacy of vitamin D3 for patient benefit. 103 
 104 
Study participants 105 
For the study involving young (<40 years) and old (≥65 years) adults (Figure 1) we recruited 106 
healthy individuals of white European ethnicity. We excluded individuals with co-morbidities 107 
that are associated with significant internal organ or immune dysfunction including heart 108 
failure, severe chronic obstructive pulmonary disease (COPD), diabetes mellitus and 109 
rheumatoid arthritis, and individuals receiving immunosuppressive treatment (e.g. oral 110 
glucocorticoids, methotrexate, azathioprine and cyclosporin) for autoimmune or chronic 111 
inflammatory diseases.  112 
For the study involving vitamin D3 (Figures 2-4), healthy older adults were recruited to take 113 
part through local GP surgeries. When individuals expressed an interest in the study they 114 
were screened and recruited according to the inclusion and exclusion criteria see 115 
Supplementary Table 1. We recruited 18 healthy older individuals, VZV skin test and saline 116 
injection were performed and biopsies were collected at 6 and 48 hours. Subsequently, 117 
individuals were given 6400IU of vitamin D3 per day for 14 weeks orally. After vitamin D3 118 
supplementation the participants repeated the same VZV skin test and skin biopsies were 119 
collected as before (see Figure 3A). Serum CRP levels were measured using a Roche 120 
cobas high sensitive immunoturbidimetric assay and 25(OH)D concentrations were 121 
measured with a Roche cobas electrochemiluminescence immunoassay (ECLIA).  122 
 123 
Skin tests 124 
VZV antigen (BIKEN, The Research Foundation for Microbial Diseases of Osaka University, 125 
Japan) or 0.9% saline solution were injected intradermally into sun unexposed skin of the 126 
medial proximal volar forearm as per manufacturer’s instructions. Induration, palpability and 127 
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the change in erythema from baseline were measured and scored on day 2 or 3 as validated 128 
and described previously(11). A clinical score (range 0-10) based on the summation of these 129 
parameters was then calculated. 130 
 131 
RNAseq analysis of skin biopsies:  132 
Three separate 3 mm punch biopsies were collected from each volunteer: one from normal 133 
(un-injected) skin, one from the saline injection site at 6 hours post-injection and one from 134 
the VZV injection site at 48 or 72 hours post-injection. Biopsies were immediately stabilised 135 
in RNAlater for cryostorage. Total RNA was extracted from bulk tissue homogenates using 136 
RNeasy Mini Kit (Qiagen) as previously described (8). Library preparation for RNAseq was 137 
performed using the Kappa Hyperprep kit (Roche Diagnostics) and sequencing was 138 
performed by the Pathogens Genomic Unit (UCL) on the Illumina Nextseq 500 (Illumina ) 139 
using the NextSeq 500/550 High Output 75 cycle kit (Illumina) according to manufacturers’ 140 
instructions, resulting in a median of 22.7 million (range 1.4-38.6 million; IQR 20.8-24.4 141 
million) 41 bp paired-end reads per sample.  142 
Module analysis: RNAseq data were mapped to the reference transcriptome (Ensembl 143 
Human GRCh38 release 99) using Kallisto (22). The transcript-level output counts and 144 
transcripts per million (TPM) values were summed on gene level and annotated with 145 
Ensembl gene ID, gene name, and gene biotype using the R/Bioconductor packages 146 
tximport and BioMart (23, 24). Downstream analyses were restricted to gene biotypes with 147 
selected BioMart annotations (protein coding, IG_C_gene, IG_D_gene, IG_J_gene, 148 
IG_V_gene, TR_C_gene, TR_D_gene, TR_J_gene, TR_V_gene), resulting in 23,402 149 
Ensembl gene IDs. 150 
Heatmap and individual gene analysis: Reads were aligned to Genome Reference 151 
Consortium Human Build 38 (GRCh38) using Hisat2(25). Samtools was used to select for 152 
reads with paired mates. Transcript assembly was carried out using StringTie (26), with 153 
gene-level Fragments per Kilobase of transcript per Million mapped read (FPKM) generated 154 
using Ballgown(27). Statistical comparisons were made on gene count estimates generated 155 
by StringTie. Genes with low expression or short transcript lengths (<200 nucleotides for the 156 
longest transcript) were removed. The count matrix was normalised using the TMM method 157 
in edgeR (version 3.22.5)(28), followed by contrast fit with voom in limma (version 158 
3.36.5)(29), treating the subject ID as a blocking variable. Genes with an adjusted p-value of 159 
less than 0.05 and expression change of greater than 2-fold up or down, were considered to 160 
be statistically significant. 161 
 162 
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Microarray data 163 
Data from previous microarray experiments were utilized in this study (8). Following robust 164 
multi-array average (RMA) normalization with the R/Bioconductor package affy (30), only 165 
unique gene name annotations were retained, selecting the probe ID with highest average 166 
expression across all samples.   167 
 168 
Transcriptional modules 169 
The gene expression modules for T cells and monocytes have been described (31, 32) and 170 
validated previously (33). The VZV-specific model was generated by the mean expression of 171 
genes in a transcriptional module comprising differential gene expression in biopsies from 172 
the site of VZV-injection in young adults as compared to normal (unmanipulated) skin. The 173 
saline-specific module was represented by the mean expression of genes in a transcriptional 174 
module comprising differentially gene expression in biopsies from the site of saline-injection 175 
in old individuals as compared to normal skin. In each case, differentially expressed genes 176 
with false discovery rate (FDR) <0.05 and log2 fold difference ≥1were identified using 177 
DeSeq2 and SARTools (34) for RNAseq data, and Mann-Whitney tests in MultiExperiment 178 
Viewer v4.9 (http://www.tm4.org/mev.html) for microarray data, based on false discovery 179 
rate (FDR) <0.05 and log2 fold difference ≥1. Gene module scores were subsequently 180 
calculated as mean expression of the constituent gene names in each module. For RNAseq 181 
data, log2-transformed TPM values were used, following the addition of a pseudocount of 182 
0.001 to enable log2 transformation. Where duplicate gene names were present in the 183 
RNAseq data, the highest log2 transcript per million (TPM) value was used for each sample. 184 
Reactome pathway enrichment among module genes was analysed with the XGR R 185 
package (35). For visualization purposes, 20 pathway groups were identified by hierarchical 186 
clustering of Jaccard indices to quantify similarity between the gene composition of each 187 
pathway. For each group, the pathway with the largest total number of genes was then 188 
selected to provide a representative annotation. 189 
 190 
Serum cytokine measurements 191 
Cytokine concentration in serum was assessed by cytometric bead array (CBA; BD 192 
Biosciences) according to the manufacturer's protocol. Samples were analysed using a BD 193 
Verse flow cytometer (BD Biosciences). The lower limit of detection for each analyte were 194 
1.5pg/mL.  195 
 196 
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Statistics 197 
Statistical analysis was performed using GraphPad Prism version 8.00 (GraphPad Software, 198 
San Diego, California, USA).  Data was assessed for normality and the subsequent 199 
appropriate statistical test was performed as indicated in the legend of each figure.   200 
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Results: 201 
Low serum 25-hydroxyvitamin D concentrations correlate with inflammatory response 202 
to saline 203 
We have shown previously that older adults exhibit an early non-specific inflammatory 204 
response to intradermal injection which is associated with a reduced delayed-type 205 
hypersensitivity responses to the VZV skin test (9). We sought to extend these findings by 206 
performing modular bioinformatic analysis, as validated previously (33). We intradermally-207 
challenged healthy young (<40 years) and old (≥65 years) individuals with VZV antigen (in 208 
individuals who had pre-existing VZV immunity) for donor characteristics see Table 1). The 209 
site of challenge in the skin was biopsied 72 hours later and RNAseq or microarray analysis 210 
was performed and compared to normal, unmanipulated, skin (Figure 1A). In line with our 211 
previous studies (8, 12), 6 hour saline injection was used as a control for non-specific 212 
(needle-injury) responses. 213 
We derived transcriptional modules (signatures) to quantify the VZV-specific cutaneous 214 
immune response (Supplementary Figure 1A and Supplementary Table 2). As expected, the 215 
expression of genes within the VZV-specific module was increased in young and old adults 216 
after skin challenge (8). However, the magnitude of the secondary response to VZV antigen 217 
was significantly  lower in older individuals compared to the young individuals (Figure 1B). In 218 
a previous study, we have observed that there was a significant accumulation of T cells at 219 
the site of VZV antigen challenge in young subjects which was greatly reduced in older 220 
adults (36). To identify if T cells are as important for a VZV response, expression of a 221 
previously generated T cell-specific gene module was used (33). We observed that following 222 
injection with VZV there was a significant increase in expression of the T cell-specific module 223 
(Figure 1C). Since the magnitude of expression of the T cell-specific module correlates 224 
directly with the number of T cells present (33), this suggested that there was an increase in 225 
T cell numbers in antigen-injected skin as compared to normal skin. Indeed, our analysis 226 
showed that the expression level of the genes in the T cell-specific module correlated 227 
directly with the magnitude of the VZV clinical score (Supplementary Figure 2).   228 
We previously showed that a monocyte-driven inflammatory response to injection is 229 
responsible for the impaired T cell response to VZV in the skin of older individuals (8, 12). 230 
We therefore created a gene module associated with non-specific saline injection based 231 
upon gene expression in 6 hour saline injected old skin. This saline-specific module was 232 
enriched in genes and pathways associated with the innate immune system and interleukin 233 
signalling (Supplementary Figure 1B, Supplementary Table 3). We confirmed that there was 234 
a significant induction of an inflammatory response in saline-injected older skin that was not 235 
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observed  in the young (Figure 1D). Consistent with our previous observation we found that 236 
enrichment of a monocyte specific module was significantly greater in saline injection sites of 237 
older compared to younger individuals (Figure 1E). Expression of the monocyte-specific 238 
module was also increased in the skin of older adults 6 hours after injection with VZV 239 
antigen (Figure 1F), confirming the non-specific recruitment of monocytes to the tissue 240 
damage caused by needle injection rather than specific to saline (12). 241 
Next, in order to evaluate the potential role of vitamin D in inflammageing, we sought to 242 
understand if vitamin D insufficiency was associated with the exaggerated non-specific 243 
monocytic inflammatory response to saline injection we found in older individuals. In keeping 244 
with this, we found that there was a significant negative correlation between serum 25(OH)D 245 
concentrations and both the expression of the saline induced transcriptional module and the 246 
monocyte module in older adults (Figure 1G and H).  247 
Therefore this data suggests that vitamin D insufficiency is associated with increased non-248 
specific inflammation in the skin of older adults. 249 
 250 
Vitamin D3 supplementation significantly improved cutaneous secondary immune 251 
response in older adults. 252 
We hypothesised that if vitamin D insufficiency may be causally related to inflammageing, 253 
and in turn mechanistically linked to attenuation of antigen specific recall responses, then 254 
vitamin D supplementation may rescue age-related diminution of recall responses. We 255 
tested this hypothesis by evaluating immune responses before and after of vitamin D 256 
replacement (6400IU of vitamin D3 per day orally for 14 weeks) among older adults (median 257 
age 69 years; 6 males and 12 females), with low concentrations of serum 25(OH)D (median 258 
43nmol [22.9-68.3nmol/L]) (Figure 2A). We utilised 6400IU/day in order to maximise our 259 
chances of elevating circulating 25(OH)D levels into high physiological range, without risking 260 
toxicity by exceeding the Tolerable Upper Intake Level (UL) of 10,000 IU/day (37). All older 261 
adults had a significant increase in their serum 25(OH)D concentrations after vitamin D 262 
replacement (Figure 2B) confirming compliance with the vitamin D supplementation regime. 263 
We observed a significant increase in VZV clinical scores after vitamin D supplementation 264 
(Figures 2C and D) using an ordinal scale clinical score (11). The increase in VZV clinical 265 
score was not due to repeated exposure of antigen, as we have shown previously that 266 
repeated exposure to VZV antigen over the same time frame as used in this study, does not 267 
increase VZV clinical score (8). 268 
We further stratified the participants into three groups based on the magnitude of their 269 
clinical response following vitamin D3 supplementation: non-improvers, who did not have an 270 
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improvement in clinical score; mild-improvers, clinical score improved by 1; improvers, those 271 
who had an improvement in their clinical score of ≥2 (Figure 2D). Analysis of the 272 
characteristics of each of these groups revealed that there were no significant differences in 273 
their ages, serum 25(OH)D or CRP concentrations at baseline (Table 2) or after vitamin D 274 
supplementation. There was, however, an increased proportion of females in the improvers 275 
when compared to the other two groups (Table 2). 276 
These data suggest that vitamin D replacement can significantly enhance antigen-specific 277 
immunity during ageing. 278 
 279 
Vitamin D3 supplementation decreased non-specific monocyte-driven inflammation 280 
Following 14 weeks of vitamin D3 replacement,  there was no significant impact on 281 
circulating inflammatory cytokine or CRP concentrations (Table 3). This suggested that the 282 
beneficial anti-inflammatory effect of vitamin D3 is specific to the site of antigen challenge in 283 
the skin. Next, we evaluated the effect of vitamin D3 supplementation on the non-specific 284 
inflammatory response to saline injection. 3mm skin biopsies were collected from normal 285 
and saline-injected skin (6 hours post-injection) pre- and post-vitamin D3 replacement. As 286 
observed previously (8, 12), there was a large proinflammatory response to saline injection 287 
in older adults which was characterised by increased expression of monocyte 288 
chemoattractants and cytokines such as CCL2, CCL8 and IL1B. The expression of the 289 
inflammatory genes was reduced after vitamin D3 supplementation (Figure 3A). Focusing on 290 
the eight most upregulated genes in response to saline prior to vitamin D3 replacement, we 291 
observed that, after supplementation these genes were no longer statistically significantly 292 
upregulated as compared to normal skin (Figure 3B). Consistent with these findings, we 293 
found that expression of both the saline-induced and monocyte transcriptional modules were 294 
significantly decreased after vitamin D3 supplementation (Figures 3C and D), suggesting that 295 
vitamin D3 supplementation can reduce the non-specific inflammation and the associated 296 
inflammatory monocyte recruitment which was associated with needle challenge in older 297 
adults. 298 
 299 
Vitamin D supplementation enhances T cell accumulation in the skin after antigen 300 
challenge 301 
We have previously shown that inflammatory monocytes recruited to the skin of older adults 302 
in response to needle challenge blocks antigen-specific T cell responses and that inhibiting 303 
monocyte infiltration can improve cutaneous immunity (12). We wanted to investigate 304 
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whether vitamin D3 supplementation could also reverse inflammatory monocytes recruitment 305 
and thus the attenuated T cell responses to VZV antigen in older adult skin. Specifically, we 306 
wanted to determine whether the decrease in monocyte infiltration following vitamin D3 307 
supplementation leads to an enhancement of T cell accumulation at the site of antigen 308 
challenge. To assess this, gene expression in VZV-injected skin (48 hours after injection) 309 
was compared by RNAseq analysis pre- and post-vitamin D3 supplementation and no 310 
significant differential overall gene expression was observed (Figure 4A). We reasoned that 311 
the heterogeneity of the effect of vitamin D3 supplementation meant that our sample size 312 
was underpowered to detect statistically consistent differences in the whole group, 313 
particularly in view of the multiple testing penalty for gene-wide analysis. Therefore, we 314 
focused our analysis on VZV-induced and T cell transcriptional modules after stratifying 315 
participants by the vitamin D3 associated improvement in their VZV clinical score, into those 316 
who were non-improvers or mild-improvers (clinical score change ≤1) as compared to 317 
improvers (clinical score change >1). We found that improvers had a significant increase in 318 
the expression of the VZV-specific module after vitamin D3 supplementation as compared to 319 
those who were mild/ non-improvers (Figure 4B). In addition, the T cell-specific module was 320 
significantly increased in VZV injected skin in the improvers but not in the mild/non-321 
improvers (Figure 4C). Interestingly, individuals whose VZV clinical score increased by ≥2 322 
had a higher expression of the T cell module in response to VZV prior to vitamin D3 323 
supplementation.  324 
Collectively, our data is consistent with a mechanistic model in which vitamin D status may 325 
enhance antigen-specific immunity by reducing non-specific monocyte driven inflammation 326 
and enhancing T cell mediated recall responses.  327 
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Discussion: 328 
In this study we confirmed that antigen-specific cutaneous immune responses were reduced 329 
in the skin of older adults (≥65 years) when compared to young (<40 years). In agreement 330 
with our previous work the reduced secondary cutaneous response was associated with an 331 
increased monocyte-derived non-specific inflammatory response to needle-challenge in the 332 
older adults. As vitamin D has a role in controlling inflammation, we investigated whether 333 
vitamin D insufficiency correlated with the increased inflammatory response that occurs in 334 
the skin after needle challenge. There was increased non-specific inflammation in response 335 
to injection (determined by increased expression of genes in the saline response module) in 336 
individuals that were most vitamin D deficient. Furthermore, we demonstrated that vitamin D3 337 
supplementation in older adults (6400 IU vitamin D3 per day for 14 weeks) significantly 338 
improved cutaneous secondary immune responses to VZV antigen. Our transcriptional 339 
analyses suggested that this increase in cutaneous immunity was associated with decreased 340 
early monocyte-driven inflammation and subsequent  increased recruitment of T cells to the 341 
site of antigen-challenge. 342 
In this paper we confirm using bioinformatic modular analysis, our earlier observation that an 343 
early (6 hours) monocyte-driven non-specific inflammatory response is observed in older 344 
adults but not in the young (8, 12). This non-specific inflammatory response is associated 345 
with worse antigen-specific cutaneous immunity, as characterised by reduced T cells present 346 
in VZV injected skin. Vitamin D3 replacement significantly reduced monocyte gene 347 
signatures in saline injected skin and increased T cell signatures in those individuals who 348 
had an improvement in their clinical score. This data proposes that vitamin D3 349 
supplementation inhibits monocyte recruitment to injected skin of older people and therefore 350 
limits monocyte-driven suppression of T resident memory (TRM) cells at the site of antigen 351 
challenge. It is interesting to note that the T cell signature only increases in VZV injected skin 352 
of individuals that had an improvement in their clinical score even though the non-specific 353 
inflammatory response is reduced in the majority of participants after vitamin D3 354 
replacement. One reason for this might be that the T cell response is only increased in those 355 
individuals who have a more measurable cell response to antigen prior to vitamin D3 356 
supplementation. 357 
Older adults have increased risk of mortality from primary infections such as influenza virus 358 
and the SARS-CoV-2 coronavirus, and have an increased risk of reactivation of persistent 359 
virus infections such as VZV leading to shingles (1, 38, 39). We have previously observed 360 
that older adults have reduced recall responses to antigens such as VZV or candida, 361 
resulting in a reduced recruitment of T cells and dendritic cells at the site of antigen 362 
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challenge (8). This defect in immunity is not due to alterations in circulating antigen-specific 363 
cells but is a consequence of inflammatory defects in the skin environment (9, 36). In this 364 
study we confirm that there is decreased recall responses in the skin of older adults as 365 
compared to young. The defect in the skin of older adults may be applicable to other tissue 366 
sites such as the lung and warrants further investigation. 367 
Vitamin D insufficiency is increased in the older adult population (20) and is considered to be 368 
due in part to decreased outdoor activity and aging-related alterations in vitamin D 369 
metabolism (40). In addition, vitamin D insufficiency in older adults is associated with frailty 370 
and increased systemic inflammation (19, 21). Previous studies have shown that vitamin D3 371 
supplementation in older adults with chronic inflammatory diseases such as osteoarthritis 372 
and heart failure significantly decreases the levels inflammatory mediators such as TNFα in 373 
the circulation (41, 42). In contrast to these earlier studies, we did not observed significant 374 
decreases in circulating inflammatory mediators after vitamin D3 supplementation in the 375 
healthy volunteers with no overt inflammatory disease, consistent with data in an 376 
independent study of  healthy older adults (43). We did however observe that vitamin D3 377 
supplementation was associated with a significant decrease in the non-specific inflammatory 378 
response to needle challenge in the skin.  379 
Vitamin D has a plethora of effects on the immune system. Indeed, it is known that vitamin D 380 
enhances the number and function of Foxp3+ and IL-10+ Tregs (13-15), and thus Tregs 381 
could directly reduce non-specific inflammation observed in the skin after needle challenge. 382 
Another important function of vitamin D is that it enhances T cell receptor (TCR) signalling, 383 
as it increases expression of PLCy and facilitates activation of T cells in response to antigen 384 
(44), suggesting an additional means by which vitamin D3 supplementation could be 385 
mediating the effects described in this study. 386 
There were limitations to this study including the study size, gender distribution and ethnic 387 
origin of the donors. Although this study had a higher proportion of female donors, we have 388 
previously observed that there is no significant difference in non-specific inflammatory 389 
response with between males and females (12). Our initial investigations in young and old 390 
individuals were carried out on people of diverse backgrounds and found no obvious 391 
difference between different racial groups (8, 9, 36). However, this study was designed to be 392 
only carried out on caucasians to exclude any potential effects of ethnic backgrounds. 393 
Further studies should now be performed to determine the impact of ethnicity, using our data 394 
on caucasians as a reference point. As our study was an experimental study to establish 395 
mechanisms, rather than confirm the efficacy of vitamin D3, it will be important to do a larger 396 
study to assess the impact of vitamin D3 replacement on cutaneous immunity. 397 
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Another important health challenge within older populations is the reduction in vaccine 398 
efficacy with increasing age when compared to younger adults (3). It has been proposed that 399 
inflammation has a detrimental effect on the functioning immune system and vaccine 400 
responses (7). Therefore there is a drive to develop therapies which can block inflammation 401 
to enhance vaccine responses. One such therapy that has been shown to improve influenza 402 
vaccine efficacy in older adults is the use of a TORC1 inhibitor. Inhibition of the mTOR 403 
pathway significantly enhances the immune response to vaccination and by doing so 404 
reduces influenza infections (45, 46). We have also demonstrated that cutaneous immunity 405 
can be enhanced by a four day course of oral treatment with p38-MAPKinase inhibitor 406 
Losmapimod (8, 12). However, the use of either inhibitor could potentially result in 407 
undesirable side effects, especially when used in the long-term. In contrast, the use of 408 
vitamin D supplementation is safe, cheap and readily available. Our data suggest that if used 409 
as part of a public health initiative targeting older adults, this has the potential to significantly 410 
improve the health-span by improving antigen-specific immunity and increasing vaccine 411 
efficacy. 412 
Vitamin D insufficiency has also been linked with worse clinical outcomes in the current 413 
COVID-19 pandemic (47). In addition, older people are more at risk of increase morbidity 414 
and mortality from infection with the Sars-CoV-2 coronavirus (48). Vitamin D is known to be 415 
important for respiratory health through the increasing production of antimicrobial peptides 416 
(such as cathelicidin) and reducing inflammation (17, 18, 49). Therefore, vitamin D3 417 
supplementation could be considered as a straightforward, cheap and safe means to help 418 
improve immunity to SARs-CoV-2 infection. 419 
Collectively, our data show that vitamin D3 supplementation could be a simple, cheap and 420 
readily available therapy that could enhance antigen-specific immunity in older adults.  421 
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Data availability statement: RNAseq data relating to the young vs old comparison (Figure 422 
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Figure 1: Decreased cutaneous immunity with age correlates 
with vitamin D insufficiency. 
A, study schematic, Young (white) and Old (grey) individuals were 
injected with either antigen or saline and biopsies were collected at 
specified time-points and RNAseq or Microarray analysis was 
performed. Samples were compared to Normal (unmanipulated; - 
[young n=5 and old n=32]) skin. B, antigen-specific gene module 
was generated and C, T cell-specific gene module in VZV injected 
skin (72 hours post-injection; young n=6 and young n=9). D, saline-
specific gene module and E, monocyte-specific gene module in 
saline injected skin (6 hours post-injection; young n=9 and old 
n=37). F, monocyte-specific gene module in VZV injected skin (6 
hours post-injection; young n=6 and young n=9). G, saline-specific 
module and H, monocyte-specific module in saline-injected skin 
from old donors was correlated with serum 25(OH)D concentrations 
(nmol/L). B-F were analysed with an unpaired t test and G and H 
were analysed by a Pearson correlation test. ** = p<0.01; *** = 
p<0.001; **** p<0.0001.  
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Figure 2: Vitamin D3 supplementation 
significantly improves VZV-specific 
cutaneous immunity. 
A, Clinical study schematic. B, Serum 
25(OH)D concentrations and C, and D, 
VZV clinical scores in older adults pre- and 
post-supplementation (n=18). B and C 
were analysed with a paired t test. *** = 
p<0.001; **** p<0.0001.  
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Figure 3: Vitamin D3 supplementation is associated with reduced inflammatory monocyte recruitment in response to saline. 
A, RNAseq analysis of 3mm biopsies collected from normal and saline-injected skin (6 hours post-injection) pre- and post-vitamin D3 
supplementation. The top 30 genes upregulated in saline injected skin as compared to normal skin before pre-Vitamin D3 and B, dot plots of top 
8 upregulated saline-associated genes pre-vitamin D3 . C, saline specific module and D, monocyte-specific module in saline injected skin pre- 
and post-vitamin D3 supplementation (n=17). B, analysed by C and D, analysed with a Wilcoxon-matched paired test. * = p<0.05; ** = p<0.01; *** 
= p<0.001; **** = p<0.0001. 
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Figure 4: Vitamin D3 supplementation increases the accumulation of T cells at the site of VZV challenge. 
A, RNAseq analysis of 3mm biopsies collected from normal and VZV-injected skin (48 hours post-injection) pre- and post-
vitamin D. The top 30 genes upregulated in VZV injected skin as compared to normal skin before post-Vitamin D3 (n=16). B, 
VZV-specific module and C, T cell specific module in VZV injected skin pre- and post-vitamin D3 supplementation separated 
based upon improvement in VZV score change of <2 (white; n=9) and change ≥2 (red; n=7). Paired data was analysed using a 
Wilcoxon-matched paired test and unpaired data with Mann Whitney test . * = p<0.05; ** p<0.01.  
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Tables: 
 Normal VZV Saline 
Characteristic Young Old Young Old Young Old 
Age 19.0  (18-23) 69.0 (65-82) 25.5 (20-27) 74.0 (66-83) 19.0  (18-23) 69.0 (65-82) 
Gender  
 
3 Male  
2 Female 
 14 Males 





5  Male 
 4 Female 
17 Male 
 20 Female 
Serum 25(OH)D 
(nmol/L) 
49 (29-88) 50.5 (25-103) No data No data 54.0 (35-88)# 52.5 (26-108) 
Number of 
donors 
5 32 6 9 9 37 
  
Table 1: Donor characteristics of young and old donors 
Data shown as median ± 10-90 Percentile. # = 3 donors had no serum 25(OH)D measurements. Normal = 
unmanipulated biopsied skin; VZV = varicella zoster virus. 
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Donor Characteristic Non-improver (NI) Mild-improver (MI) Improver (I) Significant? 
Age 70 (65-82) 73 (68-81) 69 (65-69) ns 
Gender 3 Male ; 4 Females 2 Male; 2 Female 1 Male ; 6 Females  
VZV clinical score at baseline 1 0.5 3 *** NI vs I 
CRP at baseline (mg/L) 0.8 (0.3-24.3) 0.7 (0.3-24.3) 0.8 (0.4-2.6) ns 
Serum 25(OH)D at baseline 
(nmol/L) 
40.0 (23-68) 53.0 (37-65) 42.0 (22-71)) ns 
Serum 25(OH)D after Vitamin D3 
supplementation 
(nmol/L) 
89.0 (47-102) 103.5 (87-118) 78.0 (50.0-136.0) ns 
Change in Clinical Score 0 1 2 *** NI vs I 
Number of donors 7 4 7  
  
Table 2: Donor characteristics 
Non-improvers VZV clinical score change of 0, mild improvers VZV clinical score change of 1 and improvers VZV clinical 
score change of >1 after vitamin D3 supplementation. Data shown as median ± 10-90 Percentile.  Data analysed by 
Kruskal-Wallis test. *** = p<0.001; ns = non-significant; VZV = varicella zoster virus. 
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Cytokine Pre-vitamin D3 Post-vitamin D3 P value 
CCL2 12.1pg/ml (8.47-15.7) 11.6pg/ml (8.67-14.6) 0.99 
IL-1β 0.17pg/ml (0.00-0.40) 0.15pg/ml (0.00-0.30) 0.84 
IL-6 0.60pg/ml (0.28-0.91) 0.54pg/ml (0.22-0.85) 0.58 
IL-8 6.58pg/ml (4.36-8.82) 16.0pg/ml (4.01-27.9) 0.14 
IFNα 9.68pg/ml (0.94-18.4) 8.97pg/ml (0.00-18.4) 0.48 
TNFα 0.41pg/ml (0.01-0.80) 0.60pg/ml (0.00-1.25) 0.67 
CRP 2.42 mg/L (0.00-5.16) 1.98 mg/L (0.87-3.10) 0.73 
  
Table 3: Serum inflammatory cytokines pre- and post-vitamin D3 supplementation 
Serum samples were collected pre- and post-vitamin D3 supplementation (n=18). Cytokine 
concentrations were assessed by cytometric bead array. Data shown as mean ± 95%CI. Data 
analysed by paired t test. 
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Supplementary Figure 1: pathways increased in VZV or Saline injected skin. 
Pathways upregulated in A, VZV-injected young skin 72 hours post-injection or B, Saline-injected old skin 6 hours post-injection. Ca2+ = 
Calcium; GM-CSF = granulocyte-macrophage colony-stimulating factor; GPCR = G-protein coupled receptor; HIV = human 
immunodeficiency viruses; IFN = interferon; IRF = Interferon regulatory factor; MDA = melanoma differentiation-associated protein; RIG-I = 
retinoic acid-inducible gene I; SCF-KIT = Stem cell factor-KIT; TRAF = TNF receptor-associated;  VZV = varicella zoster virus;  6h = 6 hours;  
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Supplementary Figure 2: T cell-specific gene modules significantly correlates with VZV clinical 
score. 
Correlation between  T cell-specific gene module and VZV clinical score. Analysed by Pearsons 
correlation test. 
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Inclusion Criteria Exclusion Criteria 
Age >65 years. Shingles vaccine, negative VZV serology 
Healthy as determined by the investigator or medically 
qualified designee based on a medical evaluation 
including medical history, physical examination and 
laboratory tests. 
HIV seropositive, known diabetes mellitus, current malignancy or 
any other history of neoplastic disease other than basal cell 
carcinoma in remission less than 1 year before recruitment, 
autoimmune diseases, keloid scarring, any skin disease 
Subject is capable of giving written informed consent, 
which includes compliance with the requirements and 
restrictions listed in the ICF and is willing and able to 
return for all study visits. 
Currently receiving any immunosuppressive therapy including 
corticosteroids, azathioprine, methotrexate tacrolimus or 
sirolimus, mycophenalate mofetil, Interferons, NSAIDS (excluding 
low dose aspirin), any antibody therapies or other biologics 
Serum 25-hydroxyvitamin D <75 nmol/L Any vaccination in 6 weeks before recruitment or plans for 
receiving a live attenuated vaccine during the vitamin D3 
treatment period. 
Serum corrected calcium concentration <2.65 mmol/L Currently receiving any anticoagulant therapy 
Estimated Glomerular Filtration rate (eGFR)  >30 
ml/min/1.73 m2 
Currently receiving phenytoin, barbiturate, cardiac glycoside, oral 
glucocorticoid or vitamin D3 supplement 
Platelet count ≥150,000 per microliter Other contra-indication to vitamin D3 supplementation: known 
sarcoidosis, known hyperparathyroidism or known nephrolithiasis 
International Normalised Ratio (INR) <1.1 Known allergy to vitamin D3 or its excipients 
Activated Partial Thromboplastin Time (aPTT)  ≤38 
seconds 
Use of another investigational product within 30 days or 5 half-
lives (whichever is longer) or according to local regulations, or 
currently participating in a study of an investigational device. 
 History of anaphylactic reactions to local anaesthetics. 
 
 
Supplementary Table 1 : Inclusion and exclusion criteria for the vitamin D3 clinical study 
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(See separate document containing Supplementary Table 2) 
 
 
(See separate document containing Supplementary Table 3) 
 
Supplementary Table 2: A list of genes used to generate the VZV-specific module. 
Supplementary Table 3: A list of genes used to generate the saline-specific module. 
